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Background: Chronic inflammation is a key feature of colorectal cancer (CRC), meaning that inflammatory
biomarkers may be useful for its diagnosis. In particular, high neutrophil gelatinase-associated lipocalin (NGAL)
expression has been reported in CRC. Thus, we investigated whether serum NGAL and NGAL/MMP-9 could be
potential biomarkers for the early detection of CRC. Concurrently, we studied other inflammatory biomarkers such
as soluble tumor necrosis factor receptor 1 and 2 (sTNFR-1, sTNFR-2), and C reactive protein (CRP).
Methods: The AGARIC multicenter case–control study was performed in eastern France and included patients
admitted for elective surgery either for a priori non-metastatic incident CRC (n = 224) or for benign causes (n = 252).
Pre-operative serum levels of NGAL, NGAL/MMP-9, sTNFR-1, sTNFR-2 and CRP were measured.
Results: Median values of serum NGAL, NGAL/MMP-9, sTNFR-1, sTNFR-2 and CRP were significantly higher in CRC
patients than in controls. Receiver Operating Characteristic analysis provided relatively poor values of area under the
curve, ranging from 0.65 to 0.58. Except for NGAL/MMP-9, all biological parameters were strongly correlated in CRC
cases and, less strongly in controls. Multivariate odds ratio (OR) of CRC comparing the extreme tertiles of serum
NGAL was 2.76 (95% confidence interval (CI): 1.59-4.78; p < 0.001),. Lower but significant multivariate associations
were observed for sTNFR-1, and sTNFR-2: OR = 2.44 (95% CI : 1.34-4.45, p = 0.015) and 1.93 (95% : CI 1.12-3.31),
respectively. No independent association was found between case–control status and NGAL/MMP-9. Among CRC
cases, maximal tumor size was an independent determinant of serum NGAL (p = 0.028) but this association was
reduced after adjustment for CRP (p = 0.11).
Conclusion: Despite a significant increase in serum NGAL and other inflammatory markers among CRC patients,
our findings suggest that they may not be suitable biomarkers for the diagnosis and especially early detection
of CRC.
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Colorectal cancer (CRC) is the second and third most
common cancer in women and men, respectively, and
the fourth leading cause of cancer-related death world-
wide [1,2]. Detection of CRC at an early stage is critical
since the 5-year survival rate ranges from 96% for patients
with stage I CRC to 5% for patients with stage IV CRC [3].
About half of CRCs are detected at advanced stages. Thus,
the search for new markers is of major interest for early
detection of CRC and identification of new potential
therapeutic targets.
During recent years, Neutrophil Gelatinase-Associated
Lipocalin (NGAL) gave rise to great interest in the oncol-
ogy field. NGAL is a 198 amino acid glycoprotein first iso-
lated in human neutrophils and expressed in many tissues
[4]. In normal tissues, NGAL provides protection against
bacterial infection and oxidative stress [5-8]. High NGAL
expression was reported in many inflammatory benign
diseases [9-16], as a consequence of a positive transcrip-
tional regulation by inflammatory cytokines.
The diagnostic or prognostic potential of NGAL
appears very variable according to the type of cancer. In
tissues such as thyroid, breast, endometrium, pancreas,
NGAL expression was shown to be null or weak in non-
neoplastic tissues and to increase in the presence of dyspla-
sia or neoplasia [17-23]. Moreover, some studies suggested
that NGAL could be a predictor of disease-free survival in
breast cancer [21,22,24]. Conversely, another report found
a positive association between NGAL expression and
the degree of differentiation of carcinoma cells in ovar-
ian cancer [25].
Regarding serum NGAL concentration, several studies
have reported higher levels in cancer patients than in
healthy controls, for ovarian, gastric, pancreatic and kidney
cancers [17,18,25,26]. With respect to CRC, relatively
few studies have investigated the role of NGAL in the de-
velopment and progression of the neoplastic process. In
CRC, immunohistochemical staining experiments demon-
strated that NGAL expression in normal tissue was null
or weak in 98% of cases, whereas it was moderate or in-
tense in 74% of carcinoma. Moreover, a higher proportion
of stages III and IV CRC expressed NGAL intensively
compared to stages I and II (57% versus 42%) [27]. Small-
sized studies even suggested that NGAL tissue expression
could be a marker for poor prognosis in stage I CRC
[28,29]. Previous studies having examined serum NGAL
levels provided discordant results possibly due to their
small sample size and their inability to take into account
potential confounders [27,30]. Sun et al., did not show any
significant increase in serum NGAL concentration in 39
CRC patients compared to matched controls, nor any
significant association with cancer stage [27]. Fung et al.
reported moderately higher serum NGAL concentration
without any correlation with Duke’s or T stage [31]. At theopposite, Marti et al. evidenced a 145- and 185-fold in-
crease in serum NGAL in non-metastatic and metastatic
CRC respectively, compared to controls [30].
NGAL is able to complex with MMP-9, protecting
MMP-9 from its autodegradation and consequently result-
ing in a higher gelatinolytic action of MMP-9 on extracellu-
lar matrix. By this way, MMP-9 may promote cancer
development [32,33]. Thus, serum NGAL/MMP-9 complex
could also be a marker of CRC diagnosis and/or severity.
The mechanisms underlying the increase in NGAL
expression in CRC are not fully understood, but this
increase could be linked to inflammation. Thus, other
inflammatory serum proteins may also be potential
markers for the diagnosis of CRC. While serum C-
reactive protein (CRP) concentration has been shown to
be higher in CRC patients than in controls in previous
studies [34-36], markers such as soluble Tumor Necrosis
Factor-α Receptor-1 (sTNFR-1) and sTNFR-2 have never
been studied.
Thus, the main aim of the present study was to assess,
in a large set of patients, the clinical value of serum
levels of NGAL, NGAL/MMP-9, CRP, sTNFR-1 and
sTNFR-2, for early diagnosis of CRC. Secondary aims
were to explore the inter-relationships between these po-
tential biomarkers and to examine their associations
with tumoral characteristics. This analysis was based on
the clinical and biological data collected in the AGARIC
(Acides Gras polyinsaturés, métabolisme du tissue Adi-
peux et RIsque de cancer Colorectal) case–control study
which was primarily designed to assess the role of the
fatty acid composition of adipose tissue and erythrocyte
membranes in CRC occurrence.
Methods
Study population
The AGARIC case–control study was conducted in di-
gestive surgery departments from five University hospi-
tals localized in north-eastern France (Besançon, Dijon,
Nancy, Reims and Strasbourg) between June 2008 and
June 2011. Cases were patients aged 45 years or over
consecutively admitted for elective surgery with curative
intent for a newly diagnosed primary CRC. CRC patients
were excluded if distant synchronous metastases were
known before surgery (except for a priori resectable liver
metastases), or if they had known familial adenomatous
polyposis or hereditary non polyposis CRC. However,
patients with distant metastases discovered during sur-
gery or the immediate postoperative period were kept in
the analysis. Patients were also excluded if they had
undergone pre-operative radiotherapy or chemotherapy
in order to avoid any treatment impact on biomarkers.
Control patients were aged 45 years or over, admitted in
the department for elective abdominal surgery for be-
nign diseases. They had to be free of any history of CRC
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tory of inflammatory bowel disease, or with another ma-
lignancy in progression were excluded. In the frame of
the primary purpose of the AGARIC study in the field of
nutrition, cases and control patients who displayed sig-
nificant changes in their dietary habits within the last
three months were not considered eligible. Furthermore,
patients who had a serious concomitant organic or psy-
chic disorder that would prevent the understanding of
study protocol were also excluded. A total of 224 patients
with CRC and 252 controls (105 patients with hiatus or
inguinal hernia, 75 patients with incisional hernia, 45 pa-
tients with diverticulitis and 27 patients with other benign
illnesses) fulfilled inclusion criteria.
The study was carried out in accordance with the prin-
ciples of the Declaration of Helsinki. The protocol was
approved by the local Ethics Committee (CPP Est 1,
Dijon, France) of the coordinating centre (date of ap-
proval: February 21st 2008) and the National Commission
for Data Processing and Liberties (CNIL; date of approval:
May 5th 2008). According to French law, no approval by
local ethics Committee of other study centres is required.
All patients signed written informed consent before their
inclusion in the study. The study was registered on Clini-
calTrials.gov (study NCT01966081; date of registration:
October 16th 2013.
Collection of clinical data
In each study center, clinical data were collected by the
medical staff with the help of research assistants. Infor-
mation about tumor characteristics was recorded from
surgical and pathological reports and included the cancer
site, invasion depth (pathologic T factor of the American
Joint Committee on cancer (AJCC) TNM classification),
maximal tumor size, lymph node metastasis and distant
metastasis. Pre-surgical treatment (transfusion, anticoagu-
lant drugs, antiplatelet drugs) was also recorded. Measure-
ments in the pre-operative period included systolic and
diastolic blood pressure, weight, waist and hip circumfer-
ences assessed in standing patients breathing normally.
Height and weight history was reported by patients. Body
mass index (BMI) was defined as weight (kg) divided by
height squared (m2). In each center, cases and controls
were interviewed by the same research assistant about
their personal medical history, family history of CRC
among first-degree relatives, marital status, education
level, smoking and alcohol consumption. Medications and
dietary supplements in the month preceding the inclusion
were obtained from anaesthetic reports and physician pre-
scriptions, completed by the patient’s interview. Type 2
diabetes was defined as self-reported physician diagnosis
of diabetes or fasting plasma glucose ≥ 126 mg/dL or
current treatment for diabetes. Leisure time physical
activity (walking, biking, sports activities, do-it-yourselfactivities, gardening…) was defined as high if patients
had an intensive physical activity (leading to sweating
and/or breathlessness) > 2 hours per week, as low if patients
had no intensive physical activity and a moderate activity
(not leading to sweating nor breathlessness) <1 hour per
week, and as medium in other situations. Alcohol intake
was classified in three categories according to the approxi-
mate median in drinkers: no alcohol intake, < 5 drinks per
week (reference category) and ≥ 5 drinks per week.
Biological measurements
Pre-operative blood samples (15 mL) were collected
after overnight fasting. Blood samples were immediately
stored at +4°C, processed in each study center and fro-
zen at −80°C within a maximal 4 hours. They were later
transported to the coordinating center in Dijon (France)
and then sent to the central biological laboratories
(Inserm UMR 866, Dijon, France) or stored at −80°C ac-
cording to French rules (cryopreservation in the Center
of Biological Resources Ferdinand Cabanne of the Dijon
University Hospital, France).
Glycemia and albumin were measured on aVista Dimen-
sion analyzer (Siemens Healthcare Diagnostics, Deerfield
USA) with the dedicated reagents (hexokinase and bro-
mocresol purple method, respectively). Ultrasensitive
CRP, albumin and prealbumin were quantified by immu-
nonephelemetry using the same analyzer. Insulin was
quantified by a chemiluminesent method on an Immulite
analyzer (Siemens). NGAL, NGAL/MMP-9, sTNFR-1,
sTNFR-2 were quantified by enzyme immunoassay kits
(Quantikine R&D, Systems, Minneapolis, Minn). For these
3 parameters, intra and inter assay coefficients of variation
were below 5 and 7%, respectively. Controls and cases
were mixed on each plate and all analyses were blinded.
The homeostatic model assessment of insulin resistance
(HOMA-IR) was calculated as fasting glucose (mmol/L) ×
fasting insulin (mU/L)/22.5.
Statistical methods
Descriptive characteristics were expressed as percentages
for categorical variables or medians with interquartile
range (IQR) for continuous variables. Univariate compari-
sons between groups (cases and controls) were performed
using chi-square tests or Fisher exact tests, when appropri-
ate, for qualitative variables, and using the Kruskal-Wallis
test for quantitative variables. Spearman correlation coeffi-
cient was used to assess correlations between quantitative
variables. The ability of serum NGAL, NGAL/MMP-9 and
other biological parameters (sTNFR-1, sTNFR-2, CRP) to
discriminate cancer and control patients was evaluated
using Receiver Operating Characteristic (ROC) curve ana-
lysis. The area under the curve (AUC) and 95% confidence
interval were used to assess the discriminatory power of
each biological parameter with an AUC of 1 considered







n (%) n (%)
Male gender 144 (57) 137 (61) 0.37
Median age (years) [IQR] 66.4 [58.4-74.8] 69.6 [60.6-75.9] 0.04
Median current BMI
(kg/m2) [IQR]
26.9 [24.2-30.4] 25.9 [23.3-29.8] 0.05
Median Waist/Hip
ratio [IQR]
0.93 [0.88-1.00] 0.95 [0.89-1.01] 0.12
Recent weight loss ≥5 kg 30 (12) 53 (24) <0.001
Severe denutrition 6 (2) 15 (7) 0.02
Family history of colorectal
cancer
0.06
No 220 (87) 178 (79)
Yes 22 (9) 29 (13)
Unknown 10 (4) 17 (8)
Smoking 0.72
Never smoker 113 (45) 107 (48)
Ex smoker 103 (41) 89 (40)
Current smoker 37 (15) 28 (13)
Alcohol consumption 0.08
None 47 (19) 39 (18)
<5 drinks/week 105 (42) 74 (33)
≥5 drinks/week 98 (39) 109 (49)
Physical activity 0.29
Low 65 (26) 70 (31)
Medium 139 (55) 108 (48)
High 48 (19) 46 (21)
Type 2 diabetes 40 (16) 49 (22) 0.09
Median HOMA-IR 0.81 [0.42-1.98] 0.92 [0.44-2.15] 0.28
Median pre-albumin (g/L) 0.26 [0.22-0.30] 0.23 [0.19-0.28] <0.001
Aspirin or NSAID use in
the last month
51 (20) 52 (23) 0.43
Statin use in the last month 60 (24) m 69 (31) 0.09
TNM stage
(Tis) 13 (5.8)
Stage I 57 (25.4)
Stage II 77 (34.4)
Stage III 60 (27.1)
Stage IV/unstaged 17 (7.6)
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and specificity of each biomarker was estimated at the opti-
mal cutoff value defined by the Youden Index [37].
Waist and/or hip circumferences were not available
for 11% of the patients. Missing values were handled
separately for men and women using conditional mean
imputation by linear regression with age, smoking status,
alcohol consumption, systolic blood pressure, HOMA-IR,
recent weight-loss and BMI as predictor covariates [38].
The distribution of waist/hip ratio (WHR) and its correla-
tions with other variables were preserved after imputation.
Unconditional logistic regression analyses stratified on
center were performed for NGAL, NGAL/MMP-9, sTNFR-1,
and sTNFR-2. Tertile cutpoints were determined by the
distribution of each biological parameter among controls
and the lowest tertile was used as the reference category.
Odds ratios and 95% confidence intervals (CI) were calcu-
lated to estimate the relative risk associated with tertiles of
biological parameters. Models were systematically adjusted
for age, gender, body mass index, WHR, family history of
CRC and alcohol intake which are known risk factors of
CRC. Backward selection with p-value < 0.10 to stay in the
model was performed for other patient characteristics asso-
ciated with CRC with a p-value < 0.20 in the univariate ana-
lysis. Pre-albumin, recent weight-loss and regular statin use
in the last month were retained in all models whereas dia-
betes, albumin and aspirin/non steroidal anti-inflammatory
drugs (NSAIDs) use were rejected. Selected models
were adjusted thereafter for CRP. Given that we were
especially interested in the independent association be-
tween serum NGAL and CRC, serum sTNFR-1 and
sTNFR-2 were also separately introduced into the re-
gression model. The Hosmer-Lemeshow test was used
to check models’ goodness-of-fit.
Determinants of serum NGAL, sTNFR-1 and sTNFR-2
among CRC patients were studied in a multivariate lin-
ear regression analyses systematically adjusted for age
and gender. All other variables associated with serum bio-
markers in univariate analysis at p < 0.10 were introduced
into the regression model as independent variables. Back-
ward selection procedure was used with p-value < 0.10 to
stay in the model. The selected model was adjusted for
CRP thereafter.
The significance level was p < 0.05. The statistical ana-
lyses were performed with SAS software version 9.3 (SAS
Institute Inc, Cary, NC).
Results
Comparison of patients with colorectal cancer and control
patients
As indicated in Table 1, patients with CRC were signifi-
cantly older (p = 0.04) than control patients. As expected
in this case–control study, CRC patients had a lower
median BMI (p = 0.05) than controls, experienced morefrequently a weight-loss >5 kg in the last 3 months (p <
0.001) and showed lower blood levels of pre-albumin
(p < 0.001). Family history of CRC (p = 0.06), high alcohol
consumption (p = 0.08), type 2 diabetes (p = 0.09) and statin
use (p = 0.09) tended to be more frequent in cases than in
controls but not significantly so. No significant differences
Figure 1 (See legend on next page.)
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Figure 1 Serum levels of NGAL, NGAL/MMP-9, sTNFR-1, sTNFR-2 and CRP in colorectal cancer cases and controls. The boundary of the
box closest to zero indicates the 25th percentile, a line within the box marks the median, and the boundary of the box farthest from zero
indicates the 75th percentile. The lozenge symbol indicates the mean. Error bars above the boxes indicate the maximum observation above the
third quintile (Q3) plus 1.5 multiplied by the difference between the values of the third and the first quintile (Q3-Q1). Errors bars below the boxes
indicate the minimum observation below Q1 minus 1.5× (Q3-Q1). All p values for differences between CRC cases and controls were <0.001 using
Kruskal-Wallis test.
Table 2 Spearman correlation coefficients between NGAL
and other inflammatory markers in colorectal cancer
cases and controls
CRP NGAL NGAL/MMP-9 sTNFR-1 sTNFR-2
CRP 1 0.14a 0.19b 0.43c 0.35c
NGAL 0.41c 1 0.41c 0.43c 0.44c
NGAL/MMP-9 0.15a 0.46c 1 0.15a 0.06
sTNFR-1 0.51c 0.65c 0.15a 1 0.78c
sTNFR-2 0.42c 0.59c 0.04 0.85b 1
ap < 0.05, bp < 0.01, cp < 0.001.
Correlation coefficients are indicated in bold characters for cases (n = 219) and
in italics for controls (n = 250).
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physical activity and use of aspirin/NSAIDS were observed
between cases and controls.
In univariate analyses, higher serum concentrations
of NGAL, NGAL/MMP-9, CRP, sTNFR-1, sTNFR-2 (all
p values <0.005) were observed in patients with CRC
compared to controls (Figure 1). Among cases and con-
trols, median levels (interquartile range: IQR) were re-
spectively 115 ng/mL (82–153) versus 89.5 (68–117) for
NGAL, 35.0 ng/mL (17.1-85-5) versus 26.3 (15.0-57.1)
for NGAL/MMP-9, 4.54 mg/L (1.49-13.2) versus 1.96
(0.56-5.39) for CRP, 1.76 ng/mL (1.38-2.50) versus 1.45
(1.22-2.01) for sTNFR-1 and 3.07 ng/mL (2.35-4.32)
versus 2.56 (2.11-3.36) for sTNFR-2. These results were
virtually unchanged after exclusion of control patients
with diverticulitis. The ROC analysis revealed that the
discriminative power of serum NGAL between CRC pa-
tients and controls was moderate as assessed by an area
under the curve (AUC) of 0.65 (95% CI:0.60-0.70) and
poor for NGAL/MMP-9 with an AUC of 0.58 (95%
CI:0.52-0.63). The discriminative power of other bio-
logical parameters was not better with an AUC of 0.64
(95% CI:0.59-0.69) for sTNFR-1, 0.63 (95% CI:0.58-0.68)
for sTNFR-2, and 0.63 (95% CI:0.58-0.68) for CRP. For
the optimum cutoff value of NGAL (>106 ng/mL) and
NGAL/MMP-9 (>71.7 ng/mL), sensitivites and specific-
ities were respectively 57 and 69% for NGAL and 34 and
81% for NGAL/MMP-9. The optimum cutoff values of
sTNFR-1 (>1.56 ng/mL), sTNFR-2 (>3.58 ng/mL) and
CRP (>4.45 mg/L) provide sensitivities and specificities of
66 and 58%, 41 and 79%, 52 and 71%, for each biomarker
respectively. For all biological parameters, the exclusion of
control patients with diverticulitis had only a marginal im-
pact on AUC values.
Among cases, there were strong inter-relationships be-
tween NGAL, sTNFR-1, sTNFR-2, and CRP (Table 2).
Spearman correlation coefficients were especially high
between serum NGAL and both sTNFR-1 and sTNFR-2
(p < 0.001); they were lower with CRP. Although the as-
sociation between NGAL and NGAL/MMP-9 was rela-
tively high (p < 0.001), correlation coefficients between
the complex and other serum markers were very low.
Among controls, associations between NGAL and other
serum markers were attenuated for sTNFR-1, and sTNFR-
2, although being highly significant (p < 0.001). In controls,
NGAL/MMP-9 remained highly correlated to NGAL (p <0.001) and weakly associated with other serum markers
(CRP, sTNFR-1, sTNFR-2).
Multiple logistic regression models were used to test
the associations between serum NGAL, NGAL/MMP-9,
sTNFR-1, sTNFR-2, and the risk of CRC. After adjust-
ment for known risk factors of CRC (age, gender, BMI,
WHR, family history of CRC, alcohol intake) and for sta-
tin use, recent weight loss and serum pre-albumin, we
observed a significant association between serum NGAL
and the risk of CRC (3rd versus 1st tertile, OR: 2.76; 95%
CI:1.59-4.78) (Table 3). Significant associations with the
risk of CRC were also found for sTNFR-1 and sTNFR-2
but not with NGAL/MMP-9. Further adjustment for
CRP did not affect these associations (Table 3). When
sTNFR-1 and sTNFR-2 were each concurrently consid-
ered with serum NGAL in the regression model, none of
them could enter the model with p values of 0.14 and
0.52 respectively.
Serum levels of NGAL, sTNFR-1 and sTNFR-2 according to
tumor characteristics
Tumors were located in the rectum for 48 patients
(21%), left colon for 85 (38%), right colon for 83 (37%)
and 8 patients presented multiple locations (4%). There
were no significant differences in biological parameters
by location. The distribution of TNM stages given in
Table 1 showed that only 34% of the patients had ad-
vanced CRC (stages III and IV/unstaged). As indicated
in Figure 2, serum NGAL levels significantly increased
with the invasion depth (p = 0.028) with median values
(IQR) ranging from 91 ng/mL (71–165) for Tis tumors, to
100 ng/mL (80–148) for pT1, 96 ng/mL (76–128) for pT2,
120 ng/ml (86–156) for pT3 and 146 ng/mL (106–214)
Table 3 Multivariate associations between serum levels of NGAL, sTNFR-1, sTNFR-2 and risk of colorectal cancer
Multivariate logistic modela Multivariate logistic model adjusted for CRPb
Serum marker (ng/ml) Number of case/controls OR 95% CI P valuec OR 95% CI P valuec
NGAL <0.001 <0.001
< 75 40/82 1 1
75- 104 52/85 1.42 0.81-2.50 1.43 0.81-2.50
≥ 104 127/83 2.76 1.59-4.78 2.81 1.61-4.89
NGAL/MMP-9 0.75 0.74
< 18.5 60/83 1 1
18.5-42.3 61/84 0.95 0.56-1.62 0.95 0.56-1.62
≥ 42.3 98/84 1.16 0.65-2.06 1.17 0.66-2.09
sTNFR-1 0.015 0.013
< 1.30 38/83 1 1
1.30-1.77 72/84 2.00 1.14-3.50 2.03 1.16-3.55
≥ 1.77 109/83 2.44 1.34-4.45 2.51 1.36-4.61
sTNFR-2 0.016 0.015
< 2.23 47/83 1 1
2.23-3.09 63/85 am 1.34 0.79-2.28 am 1.34 0.79-2.29
≥ 3.09 109/82 1.93 1.12-3.31 1.95 1.13-3.37
aModels were stratified on centre and adjusted for age, gender, body mass index, waist/hip ratio, family history of colorectal cancer, alcohol intake, pre-albumin,
recent weight-loss and regular statin intake in the last month.
bC reactive protein (CRP) was forced in the multivariate models (p values for association with the risk of colorectal cancer were respectively of 0.58, 0.87, 0.60, 0.69
in the NGAL, NGAL/MMP-9, sTNFR-1 and sTNFR-2 models).
cp value for trend.
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with maximal tumor size (p < 0.001) with median values
(IQR) ranging from 99 ng/ml (79–137) for tumors ≤3 cm,
to 110 ng/ml (86–158) for tumors between 3 and 4.5 cm,
113 ng/mL (81–147) for tumors between 4.5 and 6 cm
and 159 ng/mL (116–214) for tumors > 6 cm. We did not
observe any significant association between NGAL levels
and lymph node involvement (p = 0.65), distant metastasis
(p = 0.17) and TNM stage (p = 0.32). Serum levels of
sTNFR-1 tended to be associated with maximal tumor
size (p = 0.064) and lymph node involvement (p = 0.056)
whereas serum sTNFR-2 levels were only associated
with maximal tumor size (p = 0.046). No associations
were found between serum NGAL/MMP-9 and tumor
characteristics or stage (all p values >0.30).
Independent determinants of serum levels of NGAL,
sTNFR-1 and sTNFR-2
Multivariate linear regression analysis showed that, among
CRC patients, serum levels of NGAL significantly de-
creased with serum albumin (p < 0.001) and were positively
associated with WHR (p = 0.005), recent weight loss >5 kg
(p = 0.026) and maximal tumor size (p = 0.028) (Table 4).
Past and current smoking, age and male gender were not
independently associated with serum levels of NGAL. The
introduction of serum CRP in the regression model
showed that CRP was an important significant determinantof serum NGAL (p = 0.004) which reduced the effects of
other variables. Especially, the effect of tumor size on
serum NGAL was reduced by 26% and no longer reached
the significance level (p = 0.11). None of the tumoral char-
acteristics were independently associated with serum levels
of sTNFR-1 and sTNFR-2. Both inflammatory markers
were independently related to increasing age (p = 0.007
and p = 0.021 respectively), waist/hip ratio (p = 0.004 and
p = 0.019 respectively) and to decreasing albumin levels
(p = 0.037 and p = 0.019, respectively). Serum CRP was
also a strong determinant of sTNFR-1 levels (p < 0.001),
but less strongly related to sTNFR-2 levels (p = 0.058).
Last, high physical activity was only associated with de-
creasing sTNFR-2 levels (p = 0.012). The sole independent
determinants of NGAL/MMP-9 were CRP (p = 0.03) and
current smoking (p < 0.001).
Among control patients, the sole significant determi-
nants of serum NGAL were age (p < 0.001), male gender
(p = 0.021) and serum CRP (p < 0.001). The sole signifi-
cant determinants of sTNFR-1 and sTNFR-2 levels were
age (p < 0.001 for both markers), body mass index (p =
0.014 and p = 0.006, respectively) and CRP levels (p < 0.001
and p = 0.007, respectively).
Discussion and conclusions
Our case–control study demonstrated a significant in-
crease in serum NGAL levels in CRC patients compared
Figure 2 Serum NGAL concentrations according to invasion
depth (Panel A), maximal tumoral size (Panel B) and TNM stage
(Panel C) of colorectal cancer. Values are presented as medians
and interquartile ranges. Maximal tumor size was unknown in 9
patients with CRC and blood samples were missing in 5 cases.
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itional risk factors for CRC. However, the increase in
NGAL concentration was mainly confined to CRC pa-
tients with large-sized tumors or important depth invasionand was not observed in patients with lymph node, distant
metastases and TNM stage. These findings along with the
moderate discriminative power of serum NGAL suggest
that, although serum NGAL may have a potential value
for the evaluation of parietal invasion, it is not a suitable
biomarker for diagnosis of CRC. At the optimal NGAL
cutoff of 1.06 ng/mL, our estimates of sensitivity and spe-
cificity indicated that more than 40% of CRC patients
would not be diagnosed whereas more than 30% of indi-
viduals would be falsely suspected of CRC.
In our study, the increase in serum NGAL concentra-
tion in patients with CRC was moderate since NGAL
concentration was on average 28% higher in CRC pa-
tients than in controls, varying between 11% in stage 0-I
and 66% in stage IV. Our results along with those re-
ported by other studies both in the oncology field and in
other fields [14,21,25,39-41] contrast with the recent ob-
servation of 145- and 185-fold increases in serum NGAL
in non-metastatic and metastatic CRC respectively, com-
pared to controls [30]. Besides differences in study design,
the lower increase in serum NGAL in our study could be
partly explained by differences in NGAL measurement
techniques. We used a method calibrated with human re-
combinant lipocalin-2 which is considered as specific by
the manufacturer. However, both studies concur regarding
the positive association between serum NGAL levels and
tumor invasion depth and the lack of association with
lymph node status.
Our results also differ from those reported by Sun et al.
[27], who did not show any significant increase in serum
NGAL concentration in 39 CRC patients compared to
matched controls, nor any association with cancer stage.
However, the previous study observed similar trends to
ours, which could have been possibly stronger with a lar-
ger cohort. Furthermore, the different findings relative to
serum NGAL markedly contrast with the clear demon-
stration that NGAL expression gradually increases along
the adenoma-carcinoma sequence in 526 specimens of
colorectal tissue [27]. The absence of NGAL expression
was observed in 80.9% of histologically normal mucosa
specimens, 56.2% and 37.5% of adenomas with low-grade
and high-grade dysplasia respectively, and in only 5.9% of
carcinoma specimens. In addition, NGAL expression was
associated with cancer stage and tumor recurrence in
stage II cancer patients. Mc Lean et al. reported similar
results, showing that 100% of cancer lesions and 67% of
adenomas expressed NGAL in patients with CRC and
colonic adenoma, respectively [41]. In this study, serum
NGAL concentration was not measured.
At the opposite, it has been demonstrated on a pre-
clinical model of colon carcinogenesis that NGAL was
upregulated only in advanced stages of tumor progression.
This is relatively concordant with the present results that
showed a link between the serum concentration of NGAL
Table 4 Independent determinants of serum NGAL among patients with colorectal cancer in multiple linear regression
analysis
Multivariate model Multivariate model further adjusted for CRP
Regression coefficient Standard error P value Regression coefficient Standard error P value
Agea (for 10 year increase) 7.3 5.0 0.15 9.2 4.9 0.063
Male gendera 11.8 13.3 0.38 11.4 13.0 0.38
Albumin in g/L (for 1 SD increase) −18.9 5.3 <0.001 −12.8 5.8 0.030
Waist/hip ratio (for 1 SD increase) 18.9 6.6 0.005 16.4 6.5 0.013
Past smoking 21.5 11.6 0.066 20.8 11.4 0.069
Current smoking 27.4 16.1 0.092 28.1 15.8 0.078
Recent weight-loss 27.7 12.4 0.026 20.5 12.2 0.094
Tumoral size (for 10 mm increase) 5.0 2.3 0.028 3.7 2.3 0.11
CRP in mg/L (for 1 SD increase) - - - 17.2 5.8 0.004
NGAL values were expressed in ng/ml.
aAge and gender were forced in the multiple regression model.
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hand, in a recent review, Candido et al. concluded that
NGAL was upregulated in adenocarcinoma tumor sam-
ples but that its expression was reduced in metastatic sam-
ples [32]. This conclusion is in agreement with the lack of
marked difference in NGAL concentration in patients with
or without lymph node or metastasis.
Altogether, our results and those of previous studies
support the hypothesis that NGAL could contribute to
colorectal carcinogenesis [27,30]. However, there is no
clear evidence that serum NGAL could be a robust marker
for CRC diagnosis as reflected by its modest discriminative
power between cases and controls. This may be due to the
fact that NGAL is not specifically secreted by cancer cells
and may be produced by numerous tissues in response to
stress conditions, especially inflammatory states. Besides
adenocarcinoma, NGAL is also overexpressed in inflam-
matory bowel diseases and diverticulis [43]. Our multivari-
ate analysis of determinants of serum NGAL showed that
NGAL concentration was negatively correlated with albu-
min and positively with WHR, CRP and tumoral size, each
of these parameters being known to be associated with in-
flammation. Adjustment for CRP reduced, but not totally
abolished, the association between serum NGAL and tu-
moral size. In the lack of data about tumoral expression of
NGAL in our study, the possible role of inflammation for
explaining high NGAL concentrations in CRC remains
speculative. Increased serum NGAL may be simply due
to a global systemic response to the presence of cancer
as reflected by high CRP levels in CRC patients. Alter-
natively, NGAL may be secreted by tumoral cells either
under the influence of local peritumoral inflammation
or under the influence of both inflammatory cytokines
and other factors not yet identified.
The association of NGAL with MMP-9 protects MMP-9
from its autodegradation and increases the gelatinolytic
action of MMP-9 on extracellular matrix. It has beensuggested that MMP-9 may promote cancer development
by this way [32,33]. On the other hand, NGAL can also
promote cell motility and invasion of colon carcinoma
cells, in a MMP9-independent manner [44]. Serum
concentration of the NGAL/MMP-9 complex was mod-
erately higher in our CRC patients than in controls but
its discriminative power was poor, meaning that it can
not be used as a diagnosis marker for CRC. Moreover,
no associations were found between serum NGAL/
MMP-9 and tumor characteristics including depth inva-
sion or stage. Our results must be interpreted with cau-
tion because they have been obtained in serum samples,
but they do not support any important role for NGAL/
MMP-9 complex in CRC development.
There is some evidence that NGAL expression can be
induced by several cytokines and growth factors [45-47].
Our study showed strong relationships between serum
levels of NGAL and other inflammatory markers such as
sTNFR-1, sTNFR-2 and CRP both in CRC and control
patients. However, these associations were stronger in
CRC patients than in controls, further suggesting that in-
flammation due to cancer could play a predominant role.
We extended previous findings relative to CRP [34-36] by
showing that, not only serum CRP, but also serum levels
of both sTNFR-1, sTNFR-2 were higher in CRC patients
than in controls even after adjustment for risk factors of
CRC. This can be explained by the fact that sTNFR-1 is
expressed ubiquitously and can be overexpressed by epi-
thelial cancer cells, whereas sTNFR-2 is predominantly
expressed by lymphoid cells in particular by those that
infiltrate the tumor. Very few clinical or epidemiological
studies have been published regarding these biomarkers.
Only two previous nested case–control studies examined
the prospective association between plasma levels of
sTNFR-2 and the risk of CRC and provided inconsistent
results in men and women [48,49]. To our knowledge,
serum levels of sTNFR-1 and sTNFR-2 have never been
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Despite the significant increase in serum sTNFR-1 and
sTNFR-2 in CRC patients, the intensity of their associ-
ation with CRC was lower than that observed with
serum NGAL. Furthermore, both markers had a poorer
discriminative power than serum NGAL, and only pre-
sented marginal associations with tumoral size and lymph
node involvement. These observations do not support the
idea that serum sTNFR-1 and sTNFR-2 could be of inter-
est for helping diagnosis of CRC.
Our study presented some limitations. First, the cross-
sectional design precludes any temporal inference being
made and any causal conclusion being drawn from our
results. Second, this study may have been subject to se-
lection biases. CRC patients recruited in university hos-
pitals may not be representative of all CRC and, because
patients with pre-operative treatment were discarded for
other study purposes, relatively few patients with rectal
cancer were included. However, our study did not provide
any evidence that serum biomarkers depended on primary
cancer location. The recruitment of control patients op-
erated for benign diseases with possible inflammatory
background could have reduced the effect of potential
biomarkers. However, our results were not altered after
exclusion of such controls. On the other hand, our study
had the advantage of including large samples of well
characterized cases and controls which allowed poten-
tial confounders to be taken into account, and of relying
on centralized and blinded analysis of blood samples
stored in optimal conditions. Finally, we did not com-
pare NGAL and sTNFRs with usual tumoral markers
such as CEA, CA19-9. Such a comparison could have
been interesting if the markers we quantified had dem-
onstrated their potential usefulness in routine but has a
lesser interest in front of the results we observed.
In conclusion, this case–control study showed that
NGAL, NGAL/MMP9, sTNFR-1 and sTNFR-2 serum con-
centrations are higher in patients with CRC, and that
NGAL levels are especially elevated in patients with large
tumors. However, our findings do not suggest that these
serum parameters may be clinically relevant markers for
the detection of CRC and especially for early detection.
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